Tivozanib
Back to search| Scientific Name: | Tivozanib |
| Brand Name: | Fotivda |
| Company Owner: | Not Available |
| Mechanism Of Action | The VHL mutation-HIF upregulation-VEGF transcription is the main pathway implicated in the growth of renal cell carcinoma. Vascular endothelial growth factor receptors (VEGFR receptors) are important targets for tyrosine kinase inhibitors, which halt the growth of tumours. |
| Description of the Drug: | Tivozanib is a kinase inhibitor to treat adult patients with renal cell carcinoma (RCC) who have failed prior systemic therapies or experienced relapsed disease. |
| Protein Data Bank: |
Source: DrugBank Online – DrugBank.com. Retrieved 2023-01-23 from https://go.drugbank.com/drugs/DB11800
